ライフサイエンスコーパス: ribose

1 viruses that binds to the small molecule ADP-ribose.

2 otinamide's glycosidic bond yielding (tz)ADP-ribose.

3 Glc-6-P, Fru-6-P, malate, fumarate, Xyl, and ribose.

4 binding of the MERS-CoV macro domain to ADP-ribose.

5 ly abrogated by 2'O methylation of the cap 1 ribose.

6 ned at 1.43-A resolution in complex with ADP-ribose.

7 atalytic residue Glu-226 with the "northern" ribose.

8 2, Sir3, Sir4, nucleosomes, and O-acetyl-ADP-ribose.

9 (NAD(+)) to modify target proteins with ADP-ribose.

10 1-linked D-ribose of cADPR was replaced by L-ribose.

11 n of MTA phosphorylase (MtnP), 5-(methylthio)ribose-1-phosphate isomerase (MtnA), and an annotated cl

12 aining inactive against host mRNAs marked by ribose 2'-O methylation at the first cap-proximal nucleo

13 Ribose 2'-O-methylation (2'-O-Me) is the most abundant r

14 tified to mediate stronger interactions than ribose 2'-OH in both the RIalpha-cAMP binding interfaces

15 By contrast, the ribose 2'-OH of A32 seems crucial for the proper positio

16 o 14 by mutating decaprenylphosphoryl-beta-d-ribose 2-oxidase (DprE1), an essential enzyme in arabino

17 beta-ribosylation of the C2-methylated amino ribose, (2) selective Strecker reaction, and (3) ring-op

18 ved in RNA capping, a guanine-N7-MTase and a ribose-2'-O-MTase.

19 ventions suggested by this algorithm, genes (ribose 5-phosphate isomerase and ribulose 5-phosphate 3-

20 -phosphate) and nucleotide metabolism (via D-ribose 5-phosphate) was associated with perturbations in

21 ation with sugars (glucose, methylglyoxal or ribose) +/-5-15 mg/mL of aged and fresh garlic extracts.

22 id, form glycosidic linkages with ribose and ribose-5-phosphate in water to produce nucleosides and n

23 ences steady-state concentrations of 5'-GMP, ribose-5-phosphate, ketone bodies, and purines.

24 le to process an abasic rNMP (rAP site) or a ribose 8oxoG (r8oxoG) site embedded in DNA.

25 sis revealed that serine serves as a new ADP-ribose acceptor site across the proteome.

26 Nevertheless, accurate assignment of the ADP-ribose acceptor site(s) within the modified proteins ide

27 ation motif where lysine can serve as an ADP-ribose acceptor site.

28 ) fragmentation methods when determining ADP-ribose acceptor sites within complex cellular samples.

29 Ribose accumulated in Arabidopsis plants lacking AtRBSK.

30 Ribose accumulation in plants lacking AtRBSK was reduced

31 Both chlorosis and ribose accumulation were abolished upon the introduction

32 crystal structure of adenosine-5-diphosphate-ribose (ADP-ribose) in complex with non-phosphorylated a

33 metabolizes NAD(+) to adenosine diphosphate ribose (ADPR) and cyclic ADPR, regulating several proces

34 TRPM2 is activated by ADP ribose (ADPR) binding to its C-terminal cytosolic NUDT9-

35 gnition, interpretation, and turnover of ADP-ribose (ADPr) signaling.

36 sic NADase activity-cleaving NAD(+) into ADP-ribose (ADPR), cyclic ADPR, and nicotinamide, with nicot

37 ta-peptide, which increase production of ADP-ribose (ADPR).

38 Previous research has identified ribose aminooxazoline as a potential intermediate in the

39 Ribose aminooxazoline can be converted efficiently into

40 Here we describe a long-sought route through ribose aminooxazoline to the pyrimidine beta-ribonucleos

41 ribonucleotides, but at the cost of ignoring ribose aminooxazoline, using arabinose aminooxazoline in

42 Ribose analogues were weaker in DAT interaction than the

43 Chemo-enzymatic synthesis from ribose and 2,6-diaminopurine produced 2-amino-S-adenosyl

44 Chemical synthesis from ribose and 2,6-dichloropurine provided crystalline 2AMTA

45 se units or between the protein proximal ADP-ribose and a given amino acid side chain.

46 were rich in fluorescent proteins, rhamnose, ribose and arabinose, all of which could be related to c

47 how the conserved Asp-20 interacts with ADP-ribose and may explain the efficient binding of the MERS

48 expressed enzymes and chemically synthesized ribose and nucleobase, we have developed an inexpensive,

49 rbituric acid, form glycosidic linkages with ribose and ribose-5-phosphate in water to produce nucleo

50 s composed of adenine or adenosine, glycine, ribose and/or 2-furanmethanol (with and without copper)

51 the binding of the macro domain to poly(ADP-ribose) and stimulates the de-PARylation activity.

52 onstrate the involvement of Alc1, a poly(ADP-ribose)- and ATP-dependent remodeler, in the chromatin-r

53 We then tested the ability of NADH, ADP-ribose, and nicotinamide to inhibit these NAD(+)-depende

54 to the angle between the carboxylate and the ribose, and to the ribose's ring configuration.

55 n of residues predicted to interact with the ribose (Arg110) and the phosphates of the nucleotide ago

56 trong preference for DMB-ribose over adenine-ribose as substrate.

57 d out' in the dimer, increasing nuclease and ribose binding activities by 100-fold and 15-fold, respe

58 oV macro domain in the host response via ADP-ribose binding but also as a potential target for drug d

59 pitation method using well-characterized ADP-ribose binding domains to provide the first genome-wide

60 a more efficient adenosine diphosphate (ADP)-ribose binding module than macro domains from other CoVs

61 e-rich loop conformation that shapes the ATP ribose binding pocket and that is preferred in CDK2 but

62 target proteins (staphylococcal nuclease and ribose binding protein).

63 Moreover, poly(ADP-ribose) binding to the Parp9 macrodomains increases E3 a

64 We analyzed an omnipresent Rossmann ribose-binding interaction: a carboxylate side chain at

65 inucleotide phosphate (NAADP) and cyclic ADP-ribose (cADPR) are Ca(2+)-mobilizing messengers importan

66 Cyclic ADP ribose (cADPR) is a Ca(2+)-mobilizing intracellular seco

67 s, including cyclic adenosine 5'-diphosphate ribose (cADPR), and CD38 knockout studies have revealed

68 ay involving the second messenger cyclic ADP-ribose (cADPR).

69 Ribose can be used for energy or as a component of sever

70 thyl (2'-OMe) group to the 5'-end nucleotide ribose (Cap-1).

71 Ribose-carboxylate bidentate interactions in other folds

72 he latter involves the synthesis of long ADP-ribose chains that have specific properties due to the n

73 ingle ADP-ribose to a target or generate ADP-ribose chains.

74 s based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synthesised.

75 On the basis of the South (S) ribose conformation and molecular dynamics (MD) analysis

76 between different backbone, nucleobase, and ribose conformations, finely regulated by the combinatio

77 tion of bias "fingerprints" for prototypical ribose containing A3AR agonists and rigidified (N)-metha

78 lease and first step towards eliminating the ribose dependency of Cas9 to develop a XNA-programmable

79 y conserved structural domains that bind ADP-ribose derivatives and are found in proteins with divers

80 The obtained ribose derivatives are, however, very poor substrates fo

81 amate without markedly increasing glucose-to-ribose flux.

82 itrap, FT) scans, which produced intense ADP-ribose fragmentation ions.

83 ARH1, the possible unbinding pathways of ADP-ribose from non-phosphorylated and phosphorylated ARH1 w

84 l processes through covalent transfer of ADP-ribose from the oxidized form of nicotinamide adenine di

85 PARGs, which remove poly(ADP-ribose) from proteins, act in injured C. elegans GABA mo

86 uranmethanol with adenine in the presence of ribose generated kinetin and its isomer, while its react

87 Ribose-lysine (RL), ribose-glycine (RG), fructose-lysine (FL) and fructose-g

88 we monitored the thermal formation of early ribose-glycine Maillard reaction products over time by i

89 ic regulators of axon regeneration: poly(ADP-ribose) glycohodrolases (PARGs) and poly(ADP-ribose) pol

90 anding the interactions of PAR with poly(ADP-ribose) glycohydrolase (PARG) and other binding proteins

91 ing stabilization of a new target, poly (ADP-ribose) glycohydrolase (PARG) mRNA, by binding a unique

92 RP1) and the deribosylating enzyme poly-(ADP-ribose) glycohydrolase (PARG), which dynamically regulat

93 KV nsP3 macrodomain is able to hydrolyze ADP-ribose groups from mono(ADP-ribosyl)ated proteins.

94 1 (HPF1) is required for PARP1 to attach ADP-ribose groups onto the hydroxyl oxygen of the Ser residu

95 The discovery of poly(ADP-ribose) >50 years ago opened a new field, leading the wa

96 on an internal guanosine N-2, rather than a ribose hydroxyl.

97 tes to the interaction being bidentate (both ribose hydroxyls interacting with the carboxylate oxygen

98 lyze phosphoryl or nucleotidyl transfer onto ribose hydroxyls of RNA chains.

99 ile investigating potential contributions of ribose hydroxyls to catalysis by kinase ribozyme K28.

100 that the loss of protein is responsible for ribose hypersensitivity.

101 the incidence of nitrotyrosine and poly(ADP)ribose in the colon.

102 lts highlight the key role of the "northern" ribose in the interaction of cADPR with CD38.

103 e 3D(pol) Leu420 side chain interacts with a ribose in the nascent RNA product 3 nucleotides from the

104 cture of adenosine-5-diphosphate-ribose (ADP-ribose) in complex with non-phosphorylated and phosphory

105 formation of prebiotic molecules, including ribose, in an interstellar ice analog experiment.

106 nslational protein modification in which ADP-ribose is transferred from NAD(+) to specific acceptors

107 First, we show that iso-ADP-ribose (iso-ADPr), the smallest internal poly(ADP-ribose

108 etion of Parp1 rescued normal cerebellar ADP-ribose levels and reduced the loss of cerebellar neurons

109 results indicate that regulation of poly(ADP-ribose) levels is a critical function of the DLK regener

110 Ribose-lysine (RL), ribose-glycine (RG), fructose-lysine

111 an ADP-ribose-protein hydrolase for mono-ADP-ribose (MAR) and poly(ADP-ribose) (PAR) chain removal (d

112 ject to adenosine-to-inosine editing or 2'-O-ribose-methylation during neovascularization.

113 2'-O-ribose-methylation of adenosine residues, however, has b

114 The rate of miR487b editing, as well as 2'-O-ribose-methylation, is increased in murine muscle tissue

115 aled a potential functional role for the ATP ribose moiety in priming the protein for the formation o

116 e unique fragmentation properties of the ADP-ribose moiety were used to trigger targeted fragmentatio

117 regions within these molecules that require ribose nucleotides and show a direct correlation between

118 L-cIDPR", the natural "northern" N1-linked D-ribose of cADPR was replaced by L-ribose.

119 The ribose of RNA nucleotides can be 2'-O-methylated (Nm).

120 litated DNA repair via hydrolysis of polyADP-ribose on related repair proteins.

121 that GkCblS has a strong preference for DMB-ribose over adenine-ribose as substrate.

122 ent of DNA repair factors via their poly ADP-ribose (PAR) binding domains.

123 , PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2.

124 s of polymers of adenosine diphosphate (ADP)-ribose (PAR) chains, primarily catalyzed by poly(ADP-rib

125 lishes DNA damage-stimulated polymers of ADP-ribose (PAR) production and the PAR-dependent NF-kappaB

126 olase for mono-ADP-ribose (MAR) and poly(ADP-ribose) (PAR) chain removal (de-MARylation and de-PARyla

127 ifficulty associated with accessing poly(ADP-ribose) (PAR) in a homogeneous form has been an impedime

128 find that histone H1 accumulated on poly(ADP-ribose) (PAR) in vivo.

129 Poly(ADP-ribose) (PAR) is a posttranslational modification predom

130 Inhibition or genetic deletion of poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) is protective agains

131 verexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistanc

132 e (iso-ADPr), the smallest internal poly(ADP-ribose) (PAR) structural unit, binds between the WWE and

133 the posttranslational modification poly(ADP-ribose) (PAR) to facilitate repair.

134 red for DNA repair that possesses a poly(ADP-ribose) (PAR)-binding macro domain.

135 ated by the zinc finger domain and poly (ADP-ribose) (PAR).

136 (marker of RNS), poly(adenosine diphosphate-ribose) (PAR, marker of PARP activation) and IL-6, in th

137 a linear polymer of nucleotides linked by a ribose-phosphate backbone.

138 modification of serines by molecules of ADP-ribose plays an important role in signaling that the DNA

139 ose, rhamnose, xylose, mannose, fructose and ribose) plus inositol as internal standard was obtained

140 ling) and more than 60% cleavage of poly-ADP ribose polymerase (compared to less than 5% in controls

141 Assays for DNA ladder formation and poly-ADP ribose polymerase (PARP) cleavage were performed to meas

142 d is catalyzed by 11 members of the poly-ADP-ribose polymerase (PARP) family of proteins (17 in human

143 SBs) and were modestly sensitive to poly-ADP-ribose polymerase (PARP) inhibitors olaparib and BMN673.

144 gs, which is further exacerbated by poly-ADP ribose polymerase (PARP) inhibitors.

145 that the latonduine analogs inhibit poly-ADP ribose polymerase (PARP) isozymes 1, 3, and 16.

146 lar hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair mechanisms.

147 deficiency is associated with high poly(ADP) ribose polymerase 1 (PARP1) activity, low endogenous NAD

148 eas DNA repair pathways mediated by poly(ADP)ribose polymerase 1 (PARP1) serve as backups.

149 (PARylation) is mainly catalysed by poly-ADP-ribose polymerase 1 (PARP1), whose role in gene transcri

150 activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1).

151 d-joining DNA repair process and in poly ADP-ribose polymerase 1 activation.

152 as suppressors and 53BP1, DDB1 and poly(ADP)ribose polymerase 3 (PARP3) as promoters of chromosomal

153 channel (C1008-->A) or silencing of poly ADP-ribose polymerase in ECs of mice prevented PMN transmigr

154 ed DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy.

155 Inhibitors of the ADP-ribose polymerase Tankyrase (Tnks) have become lead ther

156 adenomatous polyposis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionarily c

157 effects of Wnt on Axin and find that the ADP-ribose polymerase Tankyrase (Tnks)--known to target Axin

158 MTS-4 directly cleaved and degraded poly ADP ribose polymerase-1 (a key molecule in DNA repair and ce

159 sitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.

160 cle, apoptotic genes, caspase-3 and poly ADP ribose polymerase-1 (PARP-1) cleavage) and was reversed

161 ways demonstrated the activation of poly ADP-ribose polymerase-dependent cell death in bok-deficient

162 of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.

163 omatin accumulation was enhanced in poly(ADP-ribose) polymerase (PARP) 1(-/-) compared with wild-type

164 is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown c

165 We found that poly(ADP-ribose) polymerase (PARP) activation distinguishes betwe

166 re tested for inhibitory effect of poly (ADP-ribose) polymerase (PARP) activity in vitro and in vivo.

167 n of caspase-8 and -3, cleavage of poly (ADP-Ribose) polymerase (PARP) and apoptosis.

168 nd IL-1beta) and apoptotic markers (poly(ADP-ribose) polymerase (PARP) and caspase 3).

169 Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents

170 Prior work has established that the poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNKS) antago

171 The poly(ADP-ribose) polymerase (PARP) enzymes were initially charact

172 The mammalian poly(ADP-ribose) polymerase (PARP) family includes ADP-ribosyltra

173 ng the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and the ADP-

174 Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has

175 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib synergizes

176 We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carbo

177 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously show

178 s and disruption of this pathway by Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) is toxic to

179 Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectivel

180 Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ov

181 Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as pro

182 Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as pro

183 Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promisin

184 ous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinical trials.

185 gs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack o

186 g targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors.

187 ing agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors.

188 A2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

189 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2) is

190 rectal cancer by interacting with a poly(ADP-ribose) polymerase (PARP) tankyrase.

191 ibition of the NAD-consuming enzyme poly(ADP-ribose) polymerase (PARP)-1 or supplementation with the

192 the activation of poly(adenosine diphosphate-ribose) polymerase (PARP).

193 e-3, cleaved caspase-7, and cleaved poly(ADP-ribose) polymerase (PARP).

194 bind to a composite element in the poly(ADP-ribose) polymerase 1 (PARP-1) promoter in a mutually exc

195 he nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosylating enzy

196 The nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1) has been shown to facilitat

197 ribosyl)ation mediated primarily by poly(ADP-ribose) polymerase 1 (PARP1) is responsible for the rapi

198 PAR) chains, primarily catalyzed by poly(ADP-ribose) polymerase 1 (PARP1), is crucial for cellular re

199 ROS and poly(ADP-ribose) polymerase also reduce sirtuin, PGC-1alpha, and

200 3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.

201 onuclease in cooperation with PARP1 poly(ADP-ribose) polymerase and RPA The novel gap formation step

202 and high selectivity toward other poly (ADP-ribose) polymerase enzymes.

203 al marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of ho

204 se Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular en

205 sitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition.

206 tially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, r

207 ides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatmen

208 ble and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in pa

209 The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumo

210 cal trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib in mCRPC included

211 a-ketoglutarate or treatment with a poly(ADP ribose) polymerase inhibitor protects reductive carboxyl

212 Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in

213 Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to enhance

214 received previous treatment with a poly(ADP-ribose) polymerase inhibitor.

215 ibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor.

216 onsible for cellular sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) in BRCA1-deficient

217 Poly (ADP-ribose) polymerase inhibitors (PARPis) are clinically ef

218 herapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors.

219 se inhibitors and poly(adenosine diphosphate-ribose) polymerase inhibitors.

220 ssion of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a higher apop

221 esolution at telomeres requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechanism that t

222 tivation of caspase-3, -7, -8, -9, poly (ADP-ribose) polymerase, and lamin A/C.

223 (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved dr

224 by caspase-3/7 activity and cleaved poly(ADP-ribose) polymerase, in different cell lines that support

225 s DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD(+)/ATP de

226 This activates nuclear poly(ADP-ribose) polymerase, which inhibits GAPDH, shunting early

227 s and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apoptosis ind

228 r LXRalpha complexes and identified poly(ADP-ribose) polymerase-1 (PARP-1) as an LXR-associated facto

229 s work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP-1.

230 s for studying robust responses of poly (ADP-ribose) polymerase-1 (PARP-1) to DNA damage with strand

231 at-containing protein that mediates poly(ADP-ribose) polymerase-1 (PARP-1)-dependent transcriptional

232 Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzym

233 This was linked to suppressed poly(ADP-ribose) polymerase-1 activity and was reversible on resu

234 e To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior

235 Poly(ADP-ribose) polymerase-2 (PARP-2) is one of three human PARP

236 through its N-terminal region in a poly(ADP-ribose) polymerase-dependent manner.

237 cells to olaparib, an inhibitor of poly(ADP-ribose) polymerase.

238 P and implicates hyperactivation of poly(ADP-ribose) polymerase/s as a cause of cerebellar ataxia.

239 inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DNA repair protein.

240 epicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expression and is feasible for

241 The poly(adenosine diphosphate-ribose)polymerase (PARP) family of enzymes is an importa

242 ssor (Ahrr/AhRR) and TCDD-inducible poly(ADP-ribose)polymerase (Tiparp/TiPARP) by AhR ligands were ge

243 demonstrate that the nuclear enzyme Poly(ADP-ribose)Polymerase 1 (PARP1) is a promising target for op

244 rthanatos, monitored by cleavage of poly(ADP ribose)polymerase-1 (PARP-1), or necroptosis, assessed b

245 in condensation as well as distinct poly(ADP-ribose)polymerase-1 cleavage.

246 e vault-interacting domain of vault poly(ADP-ribose)-polymerase (INT) has been used as a shuttle to p

247 ient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire re

248 atrix metalloproteinases (MMPs) and poly-ADP-ribose-polymerase-1 (PARP-1) in diabetic kidney remodeli

249 ing strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of which ha

250 mes were used to deliver a PARP-1 (poly [ADP-ribose] polymerase 1) inhibitor: AZ7379.

251 Poly ADP-ribose polymerases (PARPs) catalyze massive protein poly

252 caparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PAR

253 are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases (PARP) that regulate Wnt signaling b

254 e mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in

255 Poly(ADP-ribose) polymerases (PARPs) synthesize and bind branched

256 slational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) that mediate EBV replication

257 for sirtuins and poly(adenosine diphosphate-ribose) polymerases (PARPs), which are NAD(+)-consuming

258 ribose) glycohodrolases (PARGs) and poly(ADP-ribose) polymerases (PARPs).

259 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that function in pathways critical t

260 Various poly(ADP-ribose) polymerases which are notorious guardians of cel

261 nzymes consume NAD(+) as substrate: poly(ADP-ribose) polymerases, ADP-ribosyl cyclases (CD38 and CD15

262 me families, including sirtuins and poly(ADP-ribose) polymerases.

263 Poly[adenosine diphosphate (ADP)-ribose] polymerases (PARPs) are a family of enzymes that

264 ted following DNA damage and synthesizes ADP-ribose polymers that XRCC1 binds directly.

265 rom hepatitis E virus (HEV) serves as an ADP-ribose-protein hydrolase for mono-ADP-ribose (MAR) and p

266 ISPD is a CDP-ribitol (ribose) pyrophosphorylase that generates the reduced sug

267 ation with Parp9 enables NAD(+) and poly(ADP-ribose) regulation of E3 activity.

268 Through careful mapping of the ribose requirements of Cas9, we develop hybrid versions

269 -esters, deaza modifications of adenine, and ribose restored in place of methanocarba.

270 diazole analog in complex with Sirt2 and ADP-ribose reveals its orientation in a still unexplored sub

271 e importance of the 2' hydroxyl group on the ribose ring in determining agonist efficacy consistent w

272 synthesis of nucleoside derivatives with the ribose ring locked in the South conformation by a bridge

273 lar 180 degrees rotation of the L-nucleotide ribose ring seen in other studies, the pre-catalytic ter

274 hydrolyze derivative linkages on the distal ribose ring.

275 n the carboxylate and the ribose, and to the ribose's ring configuration.

276 The results indicated that ribose selectively formed mono-ribosylated N(6) adenine,

277 M-1, P-selectin, nitrotyrosine, and poly(ADP)ribose showed a positive staining in the inflamed colon.

278 dent mechanism involving CD38 and cyclic ADP ribose signalling.

279 ned 5HT2BR affinity, which was enhanced upon ribose substitution with rigid bicyclo[3.1.0]hexane (Nor

280 s are adenosine and inosine and that vary by ribose substitution, internucleotide linkage position, a

281 s formed via beta-hydride elimination from a ribose subunit in NAD(+).

282 x of glutamine-derived carbon into RNA-bound ribose sugar as well as metabolites associated with gluc

283 the final product signifies acquisition of a ribose sugar with an intact 2-3 vicinal diol.

284 ne could mimic the interactions of agonists' ribose, suggesting that this class of compounds could ha

285 for MUC1-induced HIF expression in rewiring ribose synthesis, which drives pyridimine production as

286 omain binds with higher affinity to poly(ADP-ribose) than to DNA.

287 th cells in the ISC niche secrete cyclic ADP ribose that triggers SIRT1 activity and mTORC1 signaling

288 yltransferases either conjugate a single ADP-ribose to a target or generate ADP-ribose chains.

289 synthesize and bind branched polymers of ADP-ribose to acceptor proteins using NAD as a substrate and

290 rolyze the nicotinamide and transfer (tz)ADP-ribose to an arginine analogue, respectively.

291 ading from NAD(+) to poly(ADP-ribose) to ADP-ribose to ATP, which supports the activity of ATP-depend

292 roteins with single units or polymers of ADP-ribose to regulate DNA repair.

293 nuclear ATP, leading from NAD(+) to poly(ADP-ribose) to ADP-ribose to ATP, which supports the activit

294 Conversely, PARPs, which add poly(ADP-ribose) to proteins, inhibit axon regeneration of both C

295 on refers to the addition of one or more ADP-ribose units onto proteins post-translationally.

296 eave the glycosidic bonds either between ADP-ribose units or between the protein proximal ADP-ribose

297 se, rhamnose, xylose, mannose, fructose, and ribose were quantified in packed roast-and-ground commer

298 butyric acid; erythritol; gluconic acid; and ribose were validated in an independent sample set with

299 icyclic core is derived from d-glucose and d-ribose, whereas the tiglyl moiety is derived from an int

300 normally unless media was supplemented with ribose, which led to chlorosis and growth inhibition.

301 ved reactions of d-xylose, d-arabinose and d-ribose with glycine, alpha-l- or beta-alanine and l-vali